SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection.
COVID-19
SARS-CoV-2
genetic divergence
multiplex RT-PCR
mutation
next generation sequencing
viral variants
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
29
04
2022
revised:
29
05
2022
accepted:
30
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Being in the epicenter of the COVID-19 pandemic, our lab tested 193,054 specimens for SARS-CoV-2 RNA by diagnostic multiplex reverse transcription polymerase chain reaction (mRT-PCR) starting in March 2020, of which 17,196 specimens resulted positive. To investigate the dynamics of virus molecular evolution and epidemiology, whole genome amplification (WGA) and Next Generation Sequencing (NGS) were performed on 9516 isolates. 7586 isolates with a high quality were further analyzed for the mutation frequency and spectrum. Lastly, we evaluated the utility of the mRT-PCR detection pattern among 26 reinfected patients with repeat positive testing three months after testing negative from the initial infection. Our results show a continuation of the genetic divergence in viral genomes. Furthermore, our results indicate that independent mutations in the primer and probe regions of the nucleocapsid gene amplicon and envelope gene amplicon accumulate over time. Some of these mutations correlate with the changes of detection pattern of viral targets of mRT-PCR. Our data highlight the significance of a continuous genetic divergence on a gene amplification-based assay, the value of the mRT-PCR detection pattern for complementing the clinical diagnosis of reinfection, and the potential for WGA and NGS to identify mutation hotspots throughout the entire viral genome to optimize the design of the PCR-based gene amplification assay.
Identifiants
pubmed: 35682933
pii: ijms23116254
doi: 10.3390/ijms23116254
pmc: PMC9181733
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the National key research and development program
ID : 2021YFC2301300
Organisme : the CAMS Innovation Fund for Medical Sciences
ID : 2021-I2M-1-061
Organisme : the National Natural Science Foundation of China
ID : 92169106
Références
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32513858
Nat Med. 2021 Jul;27(7):1131-1133
pubmed: 34045737
J Mol Diagn. 2011 Nov;13(6):583-604
pubmed: 21871973
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
R Soc Open Sci. 2020 Jun 10;7(6):200636
pubmed: 32742701
Clin Chem. 2013 Oct;59(10):1470-80
pubmed: 24014836
J Mol Diagn. 2010 Jan;12(1):109-17
pubmed: 19948821
World J Gastroenterol. 2016 Nov 21;22(43):9604-9612
pubmed: 27920481
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
J Clin Virol. 2005 Oct;34(2):104-7
pubmed: 16157260
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
J Infect. 2021 Feb;82(2):282-327
pubmed: 32800801
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508